Understanding Genetics in the Age of AI Chapter 5
Chapter 5

Your Immune System, the Body's Security Team

5.1: Two Layers of Defense

Your immune system operates in two layers, and understanding both is essential to understanding how cancer vaccines work.

The first layer is innate immunity, the rapid-response team that deploys immediately but does not distinguish one threat from another. Your skin is the most obvious innate defense: a physical barrier. Mucus traps invaders in your airways. Stomach acid destroys swallowed microbes. When something breaches these barriers, innate immune cells like neutrophils, macrophages, and natural killer (NK) cells arrive within minutes to hours, engulfing or destroying anything suspicious. The innate system is fast and effective but does not learn and does not remember.

The second layer is adaptive immunity, and it is what makes vaccines possible. The adaptive immune system is slower (days to weeks for a full response on first encounter) but specific and possessing memory. Its two main players are B-cells and T-cells, both white blood cells produced in bone marrow.

B-cells produce antibodies, Y-shaped proteins that circulate in blood and bind to specific molecular shapes on invader surfaces, marking them for destruction. T-cells come in two varieties relevant here. CD4+ helper T-cells coordinate the immune response, activating other immune cells and directing the attack. CD8+ killer T-cells (cytotoxic T-cells) identify and kill infected or cancerous cells. Each individual T-cell recognizes one specific molecular pattern, but your body maintains billions of them, collectively covering virtually every possible molecular threat. When a T-cell encounters its match, it activates, proliferates, and forms memory cells that respond faster if the same threat reappears. This is immunological memory, and it is the entire basis of vaccination.

5.2: The MHC System — How Cells Show Their ID

Every nucleated cell in your body participates in a continuous display system that functions as internal surveillance. Cells constantly chop up the proteins they produce into short fragments (peptides, typically eight to eleven amino acids long) and display them on their surface using the Major Histocompatibility Complex (MHC), also known in humans as Human Leukocyte Antigen (HLA). MHC Class I molecules, present on virtually every cell, serve as an identity display: here is a sample of what I am currently producing.

When a cell is healthy, the displayed fragments are normal cellular proteins. T-cells patrol past, inspect, recognize it as "self," and move on. When a cell is infected or when a cancer mutation causes abnormal protein production, the displayed fragments include abnormal peptides, neoantigens. A CD8+ killer T-cell whose receptor matches that neoantigen recognizes it, binds, and triggers a kill signal. The cell is destroyed.

Click the cancer cell panel to activate the T-cell kill signal →

MHC antigen display: healthy cell vs cancer cell with neoantigen and T-cell kill signal. Click the cancer cell panel to see the immune response. vs. Healthy Cell Normal peptide MHC I T-cell passes by Cancer Cell click to activate Neoantigen MHC I CD8+ T-cell ⚡ Kill signal
Every cell displays protein fragments on MHC molecules — a continuous internal surveillance feed. Cancer’s mutations produce fragments the immune system doesn’t recognize as ‘self,’ triggering a kill response.

This is why neoantigens are the key to personalized cancer vaccines, and why binding prediction matters so much. For a neoantigen to be recognized, it must bind tightly enough to the patient's specific MHC molecules to be displayed. NetMHCpan predicts how strongly any given peptide binds to any given MHC molecule. The standard threshold is an affinity below five hundred nanomolar. Peptides predicted to bind more tightly are considered potential neoantigens. This computational prediction replaced what would otherwise require expensive and time-consuming laboratory binding assays.

5.3: Why Cancer Gets Away With It

If the immune system is good at detecting abnormal cells, why does cancer ever succeed? Cancer cells evolve under selective pressure from the immune system and develop strategies for evasion. One of the most important is the PD-1/PD-L1 checkpoint pathway. Many cancer cells produce PD-L1 on their surface. When PD-L1 on a cancer cell binds to PD-1 on a T-cell, it sends a "stand down" signal. The T-cell deactivates and leaves the cancer cell alone. The cancer cell is showing a fake credential, and the T-cell backs off.

This discovery led to checkpoint inhibitors, drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo), antibodies that block the PD-1/PD-L1 interaction, removing the fake credential and letting T-cells attack. In metastatic melanoma, checkpoint inhibitors produce durable responses in thirty to fifty percent of patients, a cancer that was previously untreatable once it spread. The frontier is combining checkpoint inhibitors with personalized cancer vaccines: the vaccine teaches the immune system what to look for, the checkpoint inhibitor removes the cancer's ability to hide. This combination is in clinical trials, and the early results are strong.

Key Takeaways

  • The adaptive immune system is specific and has memory — the basis of all vaccination.
  • Every cell displays protein fragments on MHC molecules — an internal surveillance feed. Mutations produce abnormal fragments (neoantigens) that T-cells can recognise.
  • CD8+ killer T-cells destroy cells displaying unfamiliar peptides — the mechanism personalized vaccines exploit.
  • Cancer evades this by displaying PD-L1, a "stand down" signal. Checkpoint inhibitors remove this evasion mechanism.